A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo ( ) and 10 5 ( ) or 10 6 ( ) TCID 50 of bPIV3. The vaccine or n p 66 n p 64 n p 62 placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-15, and 13-16 months. Serum hemagglutination inhibition (HI) and IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured. The results indicate that antibody responses to bPIV3 vaccination are more likely to be detected by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody response can be differentiated from hPIV3-induced antibody response most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of hPIV3 primary infection.
Human parainfluenza virus type 3 (hPIV3) causes croup, bronchiolitis, and pneumonia in infants, young children, and immunocompromised persons. It is the second leading cause of bronchiolitis and pneumonia in US infants !6 months old [1, 2] . The cumulative proportion of hPIV3 primary infection increases from 62% by age 1 year to 92% by age 2 years and 100% by age 4 years [3] . Reinfection with hPIV3 occurs throughout life but is associated infrequently with lower respiratory illness [1] [2] [3] . Thus, epidemiologic data suggest that it is feasible to develop a vaccine for the prevention of hPIV3-related lower respiratory illnesses and that the vaccine needs to be given to infants !6 months old.
A live-attenuated bovine PIV3 (bPIV3) vaccine, which is antigenically related to hPIV3 [4, 5] , was safe, infectious, and im-munogenic in adults, children, and infants in phase 1 trials [6] [7] [8] . A phase 2 clinical trial was conducted to evaluate further the antibody responses and safety of multiple doses of bPIV3 vaccination in infants !6 months old, in whom maternal hPIV3 antibody may be present and confound the interpretation of antibody responses to the vaccine. Here, we characterize the antibody responses to bPIV3 vaccination and the antibody responses to hPIV3 infection in young infants.
Subjects, Materials, and Methods

Study population.
Healthy infants in 3 metropolitan areas (Pittsburgh, Chicago, and Los Angeles) were enrolled in a doubleblind, placebo-controlled trial of live attenuated bPIV3 vaccine [6] [7] [8] . Infants were assigned randomly to 3 treatment groups: placebo (tissue culture medium; ), 10 5 TCID 50 ( ) ,o r1 0 6 n p 66 n p 64 TCID 50 ( ) of bPIV3. The 3 treatment groups were not sign p 62 nificantly different in race and sex (data not shown). Four doses of study vaccine or placebo were administered by intranasal spray at ages 2, 4, 6, and 12-15 months concurrently with the routine pediatric vaccines. Five serum specimens were collected from infants at ages 2 months (before dose 1), 6 months (before dose 3 and 2 months after dose 2), 7 months (1 month after dose 3), 12-15 months (before dose 4), and 13-16 months (1 month after dose 4). This study was not designed to evaluate clinical efficacy of the vaccine. Thus, data on PIV3-related illnesses were not collected.
Serologic assays. Hemagglutination inhibition (HI) and IgA antibodies against bPIV3 and hPIV3 were measured. In the HI assays, 0.5% guinea pig red blood cells and 4 hemagglutination units of viruses (hPIV3/Washington/1957 and bPIV3/Kansas/1984) were used. The antibody titer was defined as the reciprocal of the highest serum dilution that completely inhibited hemagglutination following the standard procedure [9] . The starting serum dilution was 1:4; the cutoff level of seropositivity in the HI assays was set at 4.
Serum IgA levels against hPIV3 and bPIV3 were measured by EIA. The coating antigens used in the EIA were hemagglutininneuramidase proteins that were purified from the same viruses used in the HI assays. The hPIV3 and bPIV3 IgA levels were quantified by adjusting with a standard curve generated by using purified human IgA (ImmunoPure 31148; Pierce). On the basis of findings in serum samples from the placebo group and a cutoff level of 100 U/mL, the sensitivity and specificity were 93% and 97%, respectively, in the hPIV3 IgA assay and 88% and 95%, respectively, in the bPIV3 IgA assay, when the hPIV3 HI assay was used as the standard (Aviron, unpublished data).
Definitions. Several studies have reported that 2-month-old infants have a low risk of acquiring hPIV3 infection [1] [2] [3] 10] . In addition, all serum specimens collected at age 2 months in this study tested negative by the hPIV3 and bPIV3 IgA assays ( figure  1A ). Therefore, all the HI titers at age 2 months were considered to be of maternal origin and were used as the baseline to define seroconversion at ages 6, 7, 12-15, or 13-16 months. HI antibody seroconversion was defined as follows [11] : first, A t у4 (i.e., seropositive) and second, A t у4A 2 (0.5) (tϪ2)30/51 (i.e., HI titers у4-fold increase, assuming that the biologic half-life of maternal antibody is 51 days), where A 2 and A t represented HI titers at ages 2 and t (t 12) months; undetectable HI titer was assigned a value of 2.
Classification of antibody responses. After adjusting for maternal antibody decay, HI antibody seroconversion could be used to identify an active antibody response induced by bPIV3 vaccination or hPIV3 infection. Furthermore, hPIV3 HI antibody titers tended to be higher than bPIV3 HI antibody titers in the placebo group, but the IgA antibody levels did not show this association (data not shown). Therefore, comparison of bPIV3 and hPIV3 HI titers was used to differentiate bPIV3-induced antibody response from hPIV3-induced antibody response. Overall, we identified 4 types of antibody response: no response, primary infection, vaccination, and unclassified. No response was defined as no seroconversion to bPIV3 and hPIV3. Primary infection response was defined as seroconversion to only hPIV3 or seroconversion to bPIV3 and hPIV3 with a higher hPIV3 HI titer than bPIV3 HI titer. Vaccination response was defined as either seroconversion only to bPIV3 or seroconversion to bPIV3 and hPIV3 with a higher bPIV3 HI titer than hPIV3 HI titer. Unclassified response was defined as seroconversion to bPIV3 and hPIV3 with equal bPIV3 and hPIV3 HI titers.
Statistical analysis. Seroprevalences were used to represent the proportions seropositive. The statistical difference between 2 nominal or ordinal variables was tested by x 2 , Fisher's exact, or MantelHaenszel x 2 tests for trend, as appropriate. The Epi-info 6.02 computer program [12] was used for all statistical analyses. Figure 1A shows the seroprevalences of bPIV3 IgA and hPIV3 IgA in the 3 treatment groups at different ages. In the placebo group, the 2 seroprevalences were similar at the 5 time points and increased gradually from none at age 2 months to ∼50% at 13-16 months. This implies that the hPIV3 IgA and bPIV3 IgA assays both are capable of detecting the antibody responses to hPIV3 infection. In contrast, both vaccine groups had higher seroprevalences of bPIV3 IgA than hPIV3 IgA at ages 6, 7, 12-15, and 13-16 months, which suggests that the antibody response to bPIV3 vaccination is detected more likely by the bPIV3 IgA assay than by the hPIV3 assay. Compared with the placebo group, both vaccine groups had higher seroprevalences of bPIV3 IgA but not of hPIV3 IgA at ages 6, 7, 12-15, and 13-16 months. Figure 1B shows the seroprevalences of bPIV3 HI and hPIV3 HI antibody in the 3 treatment groups at different ages. In the placebo group, the seroprevalences of hPIV3 HI were higher than of bPIV3 HI before age 7 months, but the 2 seroprevalences were similar after age 7 months, indicating that maternal PIV3 antibodies are detected more likely by the hPIV3 HI assay than by the bPIV3 HI assay. In contrast, both vaccine groups had higher seroprevalences of bPIV3 HI than hPIV3 HI at ages 6, 7, 12-15, and 13-16 months, which suggests that the antibody response to bPIV3 vaccination is detected more likely by the bPIV3 HI assay than by the hPIV3 HI assay. Compared with that in the placebo group, both vaccine groups had higher seroprevalences of bPIV3 HI and hPIV3 HI antibodies after age 6 months.
Results
IgA and HI antibody seroprevalences.
HI antibody seroconversion. Figure 1C shows the proportions of participants with HI antibody seroconversion to bPIV3 or hPIV3. In the placebo group, the proportions of hPIV3 seroconversion represent the cumulative proportions of hPIV3 primary infection, which increased gradually from 11% at age 6 months to 50% at ages 13-16 months. In the 10 5 TCID 50 group, the proportions of bPIV3 seroconversion increased gradually from 47% after the second vaccination (age 6 months) to 86% after the fourth vaccination (ages 13-16 months). In the 10 6 TCID 50 group, the proportions of bPIV3 seroconversion increased gradually from 50% after the second vaccination to 100% after the fourth vaccination. At each time point, the placebo group had similar proportions of hPIV3 and bPIV3 seroconversion, whereas both vaccine groups had higher proportions of bPIV3 seroconversion than hPIV3 seroconversion. In addition, the 10 5 and 10 6 TCID 50 groups had higher proportions of bPIV3 seroconversion (47% and 50%, 69% and 66%, 86% and 82%, and 86% and 100%, respectively; figure 1C ) than the bPIV3 IgA seroprevalences (35% and 35%, 53% and 55%, 77% and 67%, and 81% and 79%, respectively; figure 1A ) at the 4 time points, which suggests that the antibody response to bPIV3 vaccination is more likely detected by the method based on bPIV3 HI antibody seroconversion than by that based on the bPIV3 IgA seroprevalence.
Classification of antibody responses. Table 1 shows the proportions of participants with the specified antibody responses in the 3 treatment groups. In the placebo group, the proportions with primary infection response increased gradually from 11% at age 2 months to 39% at ages 13-16 months. Only 1 infant in the placebo group was classified as having a vaccination response at ages 13-16 months. The proportion of placeborecipients with an unclassified response was 0%-12% at different ages. In the 2 vaccine groups, the proportions with primary infection response were always р8%, significantly different from that in the placebo group ( , x 2 test for trend). Cu-P ! .01 mulatively, 9 vaccine recipients (7 in the 10 5 TCID 50 group and 2 in the 10 6 TCID 50 group) were classified as having a primary infection response at some time points by ages 13-16 months. The proportions with vaccination response increased gradually from 39% after the second vaccination to 63% after the fourth vaccination in the 10 5 TCID 50 group and from 43% after the second vaccination to 78% after the fourth vaccination in the 10 6 TCID 50 group. The proportions of vaccine recipients with unclassified response were 0%-22% at different time points.
Discussion
Both the presence of maternal antibody and the potential for hPIV3 infection present a challenge to the analysis of antibody responses to bPIV3 vaccination in young infants. After adjusting for maternal antibody decay, our study demonstrates that maternal hPIV3 antibody could be differentiated from actively acquired antibody induced by hPIV3 infection or bPIV3 vaccination. Furthermore, a bPIV3-induced antibody response could be differentiated from a hPIV3-induced antibody response by comparing bPIV3 and hPIV3 HI antibody titers. In some vaccine recipients (7%-22%), antibody response could not be differentiated. This limitation could be overcome by employing neutralization assays that may have lower cross-reactivity than the HI assays [9, [13] [14] [15] . Another limitation was that we cannot exactly detect the frequency of hPIV3 reinfection without virus culture. Alternatively, we estimated the cumulative incidence of hPIV3 primary infection by using hPIV3 HI titers at age 2 months as baseline.
In a most conservative estimation, all vaccine recipients with an unclassified response were assumed to have a primary infection response. Compared with that in placebo group (in which the cumulative incidence of hPIV3 primary infection was 50%; figure 1C ), the cumulative incidence of hPIV3 primary infection by age [13] [14] [15] [16] [1] [2] [3] . Therefore, if bPIV3 vaccination could prevent infants from developing antibody profiles of hPIV3 primary infection after exposure to hPIV3, prevention of hPIV3-related LRI also might be likely. Alternatively, the reduced cumulative incidence of hPIV3 primary infection in the vaccine groups may reflect altered antibody profiles after bPIV3 vaccination rather than protective immunity against hPIV3 primary infection. An efficacy trial will be needed to assess if the immune responses induced by bPIV3 vaccination can prevent hPIV3-related illness.
